UBS Maintains Buy on Syndax Pharmaceuticals, Lowers Price Target to $37
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $37.
UBS analyst David Dai maintains Syndax Pharmaceuticals (NASDAQ:SNDX) with a Buy and lowers the price target from $38 to $37.